Objective-Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin II (AngII) to form angiotensin-(1-7) (Ang-(1-7)), which generally opposes effects of AngII. AngII infusion into hypercholesterolemic male mice induces formation of abdominal aortic aneurysms (AAAs). This study tests the hypothesis that deficiency of ACE2 promotes AngII-induced AAAs, whereas ACE2 activation suppresses aneurysm formation. Approach and Results-ACE2 protein was detectable by immunostaining in mice and human AAAs. Whole-body deficiency of ACE2 significantly increased aortic lumen diameters and external diameters of suprarenal aortas from AngII-infused mice. Conversely, ACE2 deficiency in bone marrow-derived cells had no effect on AngII-induced AAAs.
A bdominal aortic aneurysms (AAAs) affect >1 million people in the United States 1, 2 There are no validated medical therapies that favorably affect aneurysm growth and rupture, making surgery the only available treatment option for AAAs. As AAA size increases, the risk of rupture increases, and ruptured aneurysms contribute to mortality rates of 60% to 80%. [3] [4] [5] Therefore, there is a need for research to define mechanisms of AAA formation so that potential drug targets for this devastating disease can be identified.
Infusion of angiotensin II (AngII) into male mice is a commonly used animal model to gain insight into mechanisms of human AAAs. 6, 7 Similar to the human disease, AAAs that develop in response to AngII exhibit progressive leukocyte accumulation, extracellular matrix degradation, luminal expansion and thrombus. 8 Manipulation of the reninangiotensin system (RAS) pharmacologically through use of angiotensin type 1 receptor (AT1R) antagonists, 9 or genetically through angiotensin type 1a receptor deficiency, 10 substantially reduces AngII-induced AAA formation. Recent studies demonstrate that inhibition of the RAS also suppressed experimental aneurysms in an elastase-induced model. 11 Currently, it is unclear whether manipulation of the RAS is an effective mode for AAA therapy in humans. [12] [13] [14] [15] [16] However, several ongoing clinical trials (NCT01118520, NCT001904981) are either actively recruiting or in the process of evaluating efficacy of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists on either the size or expansion rate of human AAAs. Moreover, a recent study demonstrated that long-term blockade of the RAS in hypertensive patients attenuated the expansion of nonaneurysmal abdominal aorta, suggesting that RAS blockade given before advancement of aortic remodeling may slow the development of AAAs. December 2014 ACE2 is a homolog of ACE that converts AngII to angiotensin-(1-7) (Ang- (1-7) ). 18, 19 The ability of ACE2 to degrade a vasoconstrictor (AngII) and produce a vasodilator (Ang-(1-7)) provides rationale for this enzyme as a therapeutic target. Previous studies in our laboratory demonstrated that deficiency of ACE2 promoted hypercholesterolemia-induced atherosclerosis. 20 Effects of ACE2 deficiency to promote atherosclerosis seem to result from elevations in AngII and from reductions in Ang-(1-7) concentrations because coinfusion of Ang-(1-7) with AngII in Ldlr -/-mice reduced atherosclerosis. 20 Although these results suggest that manipulation of ACE2 influences atherosclerotic lesion formation, the role of ACE2 as a modulator of AAA formation and severity has not been defined.
Macrophages play an important role in the formation and progression of AngII-induced AAAs. 10, 21 Previous studies demonstrated that bone marrow deficiency of ACE2 promoted diet-induced atherosclerosis, suggesting that leukocyte ACE2 suppresses atherosclerotic lesion formation. 20 Several studies have shown that deletion of specific proteins in bone marrowderived cells can enhance [22] [23] [24] or attenuate 10, 25, 26 the formation of AAAs. It is unclear whether leukocyte ACE2 also modulates the susceptibility to AngII-induced AAAs.
Because ACE2 catabolizes AngII to Ang-(1-7), activators of ACE2 are potential therapeutics in treatment of AngIIinduced diseases. Diminazene aceturate (DIZE) has been described as an activator of ACE2 [27] [28] [29] that lowered blood pressure and endothelin-1-induced ischemic stroke when administered centrally to rats 30 and that attenuated pulmonary hypertension in rats. 29 This compound has not been examined in AngII-induced AAAs. In this study, we first determined whether ACE2 localizes to human and murine AAAs. Then, we determined effects of whole-body ACE2 deficiency on AngII-induced AAAs in Ldlr -/-mice. As a potential therapeutic modality to suppress the RAS and thereby blunt AAA formation, we administered DIZE to ACE2 wild-type (Ace2
) to determine whether ACE2 activation reduced AngII-induced AAAs. We also examined effects of whole-body ACE2 deficiency on elastase-induced AAAs in Ldlr -/-mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ACE2 Localized to Murine and Human AAAs
In serial sections of abdominal aortas from saline or AngII-infused Ldlr -/-mice, ACE2 immunostaining localized predominately to the intima and adventitia ( Figure 1 ). In AAA regions exhibiting a break in medial elastin, ACE2 immunostaining was pronounced in adventitia. ACE2 immunostaining was performed on tissue sections from human abdominal aortas and in sections from patients with AAAs ( Figure 2 ; Figure  I in the online-only Data Supplement). ACE2 localized to the intima and media of both non-and aneurysmal abdominal aorta and was also present in vaso vasorum ( Figure Figure 1 . Localization of angiotensin-converting enzyme 2 (ACE2) to abdominal aortas of Ldlr -/-mice infused with either saline or angiotensin II (AngII). Left, Nonimmune IgG. Right, ACE2 immunostaining in abdominal aortic sections from saline (top 2 panels) vs AngII-infused mice (bottom 2 panels). ACE2 staining was present in all layers of the vascular wall in aortic sections from mice in each group. Black box represents area that magnified in bottom for saline-infused mice. Bottom panels for AngII-infused mice at medial break display ACE2 immunostaining. Scale bars, 50 μm.
Ace2
+/y mice ( Figure 3C ); however, Gomoritrichrome staining was similar in AAA sections from either genotype ( Figure II in the online-only Data Supplement). We performed CD68 immunostaining in AAA sections from Ace2 +/y and Ace2 -/y mice ( Figure III in the online-only Data Supplement). At sites of medial degeneration, CD68 immunostaining was more pronounced in AAA sections from Ace2 -/y when compared with Ace2 +/y mice. We also examined effects of ACE2 deficiency on dilations of the infrarenal aorta in response to intra-aortic elastase perfusion. 31 The percentage increase in aortic diameter, quantified 14 days after elastase perfusion, was not significantly different between Ace2 +/y and Ace2 -/y Ldlr -/-mice ( Figure IV in the online-only Data Supplement).
Leukocyte ACE2 Deficiency Had No Effect on AngII-Induced AAAs
Previous studies demonstrated that ACE2 deficiency in whole bone marrow cells augmented diet-induced atherosclerosis. 20 Because macrophages are a prominent cell type in AngIIinduced AAAs, 8 Figure 5A ; P<0.05) and external diameters of suprarenal aortas ( Figure 5B ; P<0.05) and also decreased significantly AAA incidence (from 73% to 29%; Figure 5C ; P<0.05). In contrast, administration of DIZE to ACE2-deficient male mice infused with AngII had no effect on aortic lumen diameters (Ace2 
Discussion
We first demonstrated that ACE2 localized to murine AngIIinduced AAAs and human AAAs. To determine whether ACE2 modulates AAA formation, we examined the effects of ACE2 deficiency on formation and severity of AngII-induced AAAs. Whole-body ACE2 deficiency promoted both formation and the severity of AngII-induced AAAs. In contrast, whole-body ACE2 deficiency had no effect on elastase-induced AAAs. Leukocyte ACE2 seemed to play no role because ACE2 deficiency in whole bone marrow cells had no effect on AngII-induced AAAs. Because ACE2 deficiency promoted AAA formation, we turned to therapeutic activation of ACE2 to suppress AAA formation and severity. Administration of the ACE2 activator, DIZE, reduced the size, severity, and incidence of AngII-induced AAAs in wild-type, but not in ACE2-deficient mice. These results suggest that ACE2 activation may serve as a novel therapeutic target in the treatment of AAAs in patients with an activated RAS.
An interesting feature of ACE2 is that it catabolizes AngII to form Ang-(1-7), 2 angiotensin peptides that counterbalance each other in vaso-contractile versus vaso-relaxation, respectively. [32] [33] [34] [35] [36] [37] [38] [39] [40] This makes activation of ACE2 an attractive target to reduce the relative balance of AngII/Ang-(1-7) and thereby inhibit vascular disease. 41 In this study, although whole-body deficiency of ACE2 promoted AngII-induced AAAs, ACE2 activation inhibited AngII-induced AAAs. Beneficial effects of ACE2 manipulation against AAA formation could result from the regulation of AngII concentrations (eg, plasma concentrations increased in ACE2-deficient mice) or from regulation of Ang-(1-7) concentrations (eg, plasma concentrations increased with DIZE administration). Plasma AngII concentrations were increased by ACE2 deficiency, but not altered in AngII-infused mice administered DIZE. However, both manipulations influenced AngII-induced AAAs, suggesting that plasma AngII concentrations are not the primary mechanism of action of ACE2. In contrast, whole-body ACE2 deficiency had no effect on AAAs induced by intra-aortic elastase perfusion. Recent results demonstrate that blockade of AT1 receptors provides benefit against elastase-induced AAA formation. 11 Moreover, whole-body AT1a receptor deficiency totally abolished AngIIinduced AAAs, 10 demonstrating a critical role for AngII effects at AT1 receptors in both of these experimental AAA models. If ACE2 deficiency augmented AngII-induced AAAs by elevating AngII concentrations available to act at AT1 receptors, then we would have anticipated that ACE2 deficiency would have similar effects in both experimental AAA models (similar to AT1 receptor blockade). Given the diverging effects of ACE2 deficiency between the AngII-and the elastase-induced AAAs, these results suggest that effects of ACE2 may be attributed to regulation of Ang- (1-7) .
In contrast to previous findings demonstrating a role for leukocyte ACE2 in diet-induced atherosclerosis, 20 results from this study demonstrate that leukocyte ACE2 deficiency had no effect on AngII-induced AAAs. However, AAAs from ACE2-deficient mice exhibited pronounced macrophage immunostaining at sites of medial degeneration. Because leukocyte ACE2 deficiency had no effect on AngII-induced AAAs, it is likely that ACE2 deficiency in other cell types (eg, vascular wall cells) promoted macrophage recruitment to developing AAAs. It is clear that angiotensin type 1a receptors are required for AngIIinduced AAAs. 10 Similar to the lack of effect of leukocyte ACE2 deficiency on AngII-induced AAAs, deficiency of angiotensin type 1a receptors on leukocytes did not significantly influence AngII-induced AAAs in Ldlr -/-mice. 10 In addition, recent studies demonstrated that neither endothelial nor smooth muscle cell angiotensin type 1a receptor deficiency influenced AngIIinduced AAAs in male Ldlr -/-mice. 42 Thus, the primary cell type(s) responding to AngII to induce AAA formation have not been identified. Additional studies should address cell type(s) expressing ACE2 that modulate local angiotensin peptide concentrations to promote AAA formation and severity.
Whole-body deficiency of ACE2 in the present study resulted in an increased blood pressure response to AngII infusion. In mice, infusion of norepinephrine to hypercholesterolemic male mice at a rate that increased blood pressure to a similar extent as observed in AngII-infused mice did not result in AAA formation. 43 Moreover, administration of the vasodilator hydralazine to AngII-infused mice had no significant effect on AAA formation. Given these findings, it is unlikely that blood pressure increases in ACE2-deficient mice infused with AngII contributed to increases in AAA severity.
Because there are no proven medical therapies that modify AAA growth and rupture, an important finding of the present study was the ability of ACE2 activation to reduce the formation and severity of AngII-induced AAAs. We used DIZE, a compound previously shown to activate ACE2 and lower blood pressure and endothelin-1-induced ischemic stroke when administered centrally to rats. 30, 44 Recent studies demonstrated that administration of DIZE not only prevents the development of pulmonary hypertension in rats but also arrests the progression of established pulmonary hypertension. 29 However, recent studies indicate that DIZE may also exhibit ACE2-independent effects. 45 We included the drug stabilizer, antipyrine, to improve the stability of DIZE because the drug has a short half-life. 46 Our results also demonstrate that DIZE increased ACE2 mRNA abundance and elevated plasma Ang-(1-7) concentrations. These findings are in agreement with results from studies using pulmonary hypertensive rats, where DIZE administration significantly increased the ACE2/ACE ratio. 29 Importantly, administration of DIZE to ACE2-deficient mice had no effect on AngII-induced AAAs, supporting an ACE2-dependent mechanism of the compound. In addition to efficacy to decrease AAA formation and severity, DIZE administration resulted in other ACE2-dependent (sera cholesterol) and ACE2-independent (body weight) effects, suggesting ancillary properties of the compound. These results support the need to include ACE2-deficient mice in studies examining novel ACE2 activators to define the specificity of drug action on the parameter of interest. In addition, these results support further studies examining efficacy of ACE2 activation to retard AAA progression.
It is noteworthy that DIZE administration reduced sera cholesterol concentrations, specifically very low-density lipoprotein-cholesterol, in wild-type but not in ACE2-deficient mice. Mechanisms responsible for ACE2-mediated regulation of sera cholesterol concentrations are unclear. Recent studies identified novel effects of ACE2 to regulate dietary amino acid homeostasis in the gut; effects that were independent of ACE2-mediated regulation of the RAS. 47 In addition to the gut, ACE2 is also expressed in liver 48 where it has been suggested to modulate cirrhosis. It is conceivable that ACE2 exerts unidentified effects, potentially related to the gut and liver, to influence cholesterol absorption and metabolism. Effects of DIZE to reduce sera cholesterol concentrations may result from increased levels of systemic Ang-(1-7) because recent studies demonstrate that administration of an oral formulation of Ang-(1-7) to high-fat-fed mice significantly reduced sera cholesterol concentrations. 49 Although beneficial in the treatment of atherosclerosis, reductions (32%) in sera cholesterol are unlikely to be the mediator of DIZE's ability to decrease AAA formation in response to AngII because sera cholesterol concentrations in mice administered DIZE (571 mg/ dL) remained considerably higher than those typically present in C57BL/6 mice (<80 mg/dL). Even at low levels of sera cholesterol concentration, male C57BL/6 mice continue to exhibit some susceptibility (20%-30%) to AngII-induced AAAs. 50, 51 In conclusion, results from these studies support a role for ACE2 as a modulator of the formation and severity of AngIIinduced AAAs. Whole-body, but not leukocyte deficiency of ACE2, promoted AngII-induced AAAs, suggesting that ACE2 in other cell types regulates AAA formation and severity. Finally, the activation of ACE2 suppressed both the formation and the severity of AngII-induced AAAs, identifying ACE2 as a potential novel target in the medical therapy of AAAs in patients with an activated RAS.
Abdominal aortic aneurysms (AAAs) and ruptures are associated with significant mortality. Currently, there are no drug therapies that are effective to slow the progression of AAAs. Infusion of angiotensin II induces AAA formation in experimental mice. Angiotensin-converting enzyme 2 (ACE2) catabolizes angiotensin II to form its functional antagonist, angiotensin-(1-7). Our results demonstrate that ACE2 localizes to murine and human AAAs. To determine the functional role of ACE2 in AAA formation and severity, we examined effects of ACE2 deficiency versus ACE2 activation on angiotensin II-induced AAAs. Deficiency of ACE2 augmented AAA formation and severity, whereas increasing ACE2 activity therapeutically suppressed AAA formation and severity. However, ACE2 deficiency had no effect on elastase-induced AAAs. These results suggest that ACE2 activators may serve as a novel therapeutic modality to reduce the formation and severity of AAAs in patients with an activated renin-angiotensin system.
Significance
